A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY OF ORAL PF-06651600 AND PF-06700841 AS INDUCTION AND CHRONIC THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
Latest Information Update: 13 Sep 2023
At a glance
- Drugs Brepocitinib (Primary) ; Ritlecitinib (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms VIBRATO
- Sponsors Pfizer
- 14 Nov 2022 Results (A cross study dose response analysis of five Phase 2 studies N=218, NCT03963401; N=212, NCT02969018; N=167, NCT02958865; N=94, NCT02974868;N=100 NCT04092452 ) assessing Pharmacologic and Clinical Rationale Brepocitinib for the Treatment of Dermatomyositis presented at the ACR Convergence 2022
- 11 Oct 2022 Results (n=280) assessing the efficacy and safety of ritlecitinib and brepocitinib in patients with moderate to severe active ulcerative colitis from the chronic dosing 24-week period of the VIBRATO study, presented at the 30th United European Gastroenterology Week.
- 11 Aug 2021 This trial has been completed in Bulgeria, according to European Clinical Trials Database record.